GEMSİTABİN'E BAĞLI KUTANOZ TOKSİSİTE GELİŞEN KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ

Öz

Gemsitabin kısmen iyi tolere edilebilen; küçük hücreli dışı akciğer karsinomu, meme, over, pankreas ve baş boyun kanserlerinde yaygın kullanım alanı kazanmış bir ilaçtır. Kemik iliği süpresyonu, bulantı, kusma benzeri semptomlar, alerjik reaksiyonlar gibi sistemik yan etkilerinin yanında yaygın olarak dermatolojik toksisiteler de görülebilir. Alopesi, raş, makülopapüler erüpsiyonlar ve diğer nadir görülen lezyonlar gemsitabin tedavisi sürecinde görülebilmektedir. Çalışmamızda evre 4 akciğer adenokarsinomu tanısıyla, ilk kez gemsitabin içeren ikili kemoterapi aldıktan sonra tüm vücudunda yaygın makülopapüler özellikte döküntüler ortaya çıkan 49 yaşındaki erkek hasta ele alınmıştır.

Anahtar Kelimeler

• Makulopapüler döküntü, gemsitabin, akciğer kanseri

NON SMALL CELL LUNG CARCINOMA WITH GEMCITABINE INDUCED CUTANEOUS TOXICITY

Öz

Gemcitabine is considerably well tolerated agent, that is often used for; non small cell lung carcinoma, breast, over, pancreas and head-neck malignancies. It's likely to have dermatologyical reactions, furthermore it has systemic side effects like pancytopenia, nausea, vomitting, flu-like symptoms and allergic reactions. Alopecia, maculopapullar eruptions, erytematous lesions and other derma- tologycal toxicities can occur during gemcitabine treatment. In our study we investigated a fourty nine year old patient with stage 4 lung adeno- carcinoma, that had diffus maculopapullar lesions after his first time combine chemoterapy with gemcitabine.

Anahtar Kelimeler

• Maculopapullar rush, gemcitabine, lung cancer

Kaynakça

1. 1. Öztürk N, Erbaycu AE, et al. ‹leri ve lokal ileri evre küçük hücreli d›fl› akci¤er kanserinde gemsitabin ve karboplatin kombinasyonu. Türk Onkoloji Dergisi 2008; 23: 72-80.
2. 2. Chu CY, Yang CH, Chiu HC. Gemcitabineinduced acute lipodermatosclerosis-like reaction. Acta Derm Venereol 2001; 81: 426-8.
3. 3. Schwartz BM, Khuntia D, Kennedy, et al. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy Gynecol Oncol 2003; 91: 421-2.
4. 4. Marucci G, Sgarbanti E, et al. Gemcitabineassociated CD8+ CD30 pseudolymphoma. Br J Dermatol 2001; 145: 650-2.
5. 5. Del pozo J, Marthinez W, et al. Linear immunoglobulin A bullous dermatosis induced by gemcitabine. Ann Pharmacother 2001; 35: 891-3.
6. 6. Bessis D, Guillot B, et al. Gemcitabineassociated scleroderma-like changes of the lower extremities. Am Acad Dermatol 2004; 51: 573-6.
7. 7. D’Alessandro V, Errico M, et al. Case report: acro-necrosis of the upper limbs caused by gemcitabine therapy. Clin Ter 2003; 154: 207-10.
8. 8. Bar-Sela G, Beny A, et al. Gemcitabine– induced radiation recall dermatitis: Case report. Tumori 2001; 87: 428-30.

9. 9. Burstein H J. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18: 693-4.
10. 10. Castellano D, Hitt R, et al. Side effects of chemoterapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18: 695-6.
11. 11. Schwartz BM, Khuntia D, et al. Gemcitabineinduced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 2003; 91: 421-2.
12. 12. Fakih MG. Gemcitabine induced rectus abdominus radiation recall. JOP 2006; 7: 306-10.
13. 13. Fogarty G, Ball D, et al. Radiation recall reaction following gemcitabine. Lung Cancer 2001; 33: 299-302.
14. 14. Jeter MD, Janne PA, et al. Gemcitabineinduced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53: 394-400.
15. 15. Chu CY, Yang CH, et al. Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment. Acta Derm Venereol 2002; 82: 147-8.
16. 16. Zustovich F, Pavel P, et al. Erysipeloid skin toksicity induced by gemcitabine. J Eur Acad Dermatol Venereol 2006; 20: 757-8.
17. 17. Kuku I, Kaya E, et al. Gemcitabine–‹nduced erysipeloid skin lesions in a patient malignant mesothelioma. J Eur acad Dermatol Venereol 2002; 16: 271-2.
18. 18. Sommers KR, Kong KM, et al. StevensJohnson syndrome /toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs 2003; 14: 659-62.